Article
Rheumatology
Monica M. Yang, Kimberly E. Taylor, Diana Paez, Alex Carividi, Emanuel Demissie, Niti Pawar, Alia A. El-Qunni, Lily E. McMorrow, Rebecca E. Schriefer, Katherine Huang, Baylee Kinnett, Michael Klebert, Alem Haile, Jane A. O'Halloran, Rachel M. Presti, Wooseob Kim, Ali H. Ellebedy, Matthew A. Ciorba, Michael A. Paley, Parakkal Deepak, Alfred H. J. Kim, Patricia Katz, Mehrdad Matloubian, Mary Nakamura, Lianne S. Gensler
Summary: This study found that patients with chronic inflammatory disease (CID) have a distinct reactogenicity profile following SARS-CoV-2 vaccination compared to controls. Furthermore, there is an association between increased reactogenicity and increased vaccine response. This finding may be an important indicator of vaccine response to the novel SARS-CoV-2 vaccines in CID patients.
ARTHRITIS CARE & RESEARCH
(2022)
Article
Immunology
Koos P. J. van Dam, Luuk Wieske, Eileen W. Stalman, Laura Y. L. Kummer, Jesse Roosen, Zoe L. E. van Kempen, Joep Killestein, Adriaan G. Volkers, Laura Boekel, Gerrit J. Wolbink, Anneke J. van der Kooi, Joost Raaphorst, Mark Lowenberg, R. Bart Takkenberg, Geert R. A. M. D'Haens, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cecile A. C. M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horvath, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renee C. F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adaja E. Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim B. D. Keijser, Olvi Cristianawati, Theo Rispens, Anja ten Brinke, Niels J. M. Verstegen, S. Marieke van Ham, Sander W. Tas, Taco W. Kuijpers, Filip Eftimov
Summary: This study aimed to assess changes in disease activity after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases (IMIDs) and identify risk factors for increased disease activity. The results showed that a minority of patients reported increased disease activity after vaccination, but most cases were mild. Disease-related factors were found to have a major impact on the increased disease activity, rather than the vaccinations themselves.
JOURNAL OF AUTOIMMUNITY
(2023)
Article
Immunology
Yufei Wu, Ping Huang, Mingjie Xu, Qianqian Zhao, Yihui Xu, Shuyi Han, Huanjie Li, Yunshan Wang
Summary: Monitoring the dynamic change in neutralizing antibodies is necessary after COVID-19 vaccination. The rate of reduction of SARS-CoV-2 neutralizing antibody levels gradually showed after booster doses. CD25+T cell expression was significantly higher in the 18-35 age group. Booster vaccination in older adults and regular testing of neutralizing antibodies are recommended if the antibody level falls below 30% inhibition rate.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Neurosciences
Salvatore Iacono, Vincenzo Di Stefano, Paolo Alonge, Claudia Vinciguerra, Giammarco Milella, Francesca Caputo, Piergiorgio Lasorella, Gabriele Neto, Antonia Pignolo, Angelo Torrente, Antonino Lupica, Paola Ajdinaj, Alberto Firenze, Stefano Tozza, Fiore Manganelli, Antonio Di Muzio, Giuseppe Piscosquito, Filippo Brighina
Summary: Neuropathic patients showed a high level of adherence to COVID-19 vaccination, and the safety of vaccines in these patients was comparable to the general population, especially for those with inflammatory neuropathy.
Article
Immunology
Amy C. Sherman, Michael Desjardins, Chi-An Cheng, Bruce Bausk, Natalie Izaguirre, Guohai Zhou, Jonathan Krauss, Nicole Tolan, David R. Walt, Robert Soiffer, Vincent T. Ho, Nicolas C. Issa, Lindsey R. Baden
Summary: This study describes the humoral response and reactogenicity profile of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in allogeneic hematopoietic stem cell transplant recipients. The findings showed that 75.0% to 80.0% of HSCT recipients had a positive antibody response after vaccination, compared to 100% in the healthy cohort.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Immunology
Andrea Picchianti Diamanti, Maria Manuela Rosado, Emanuele Nicastri, Giorgio Sesti, Claudio Pioli, Bruno Lagana
Summary: Researchers worldwide are working on developing target vaccines for the novel coronavirus and improving the management of immunomodulating agents. Patients with autoimmune rheumatic diseases appear to have a slightly higher risk in COVID-19, and caution is needed to optimize vaccine safety and effectiveness for this group.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes, A. Sidney Barritt IV, Matthew J. Armstrong, Luke Baldelli, James Kennedy, Carolyn Mercer, Ann-Kathrin Ozga, Christian Casar, Christoph Schramm, Andrew M. Moon, Gwilym J. Webb, Ansgar W. Lohse
Summary: Patients with autoimmune hepatitis (AIH) did not have an increased risk of adverse outcomes compared to other causes of chronic liver disease (CLD) and to matched cases without liver disease, despite the use of immunosuppressive treatment.
JOURNAL OF HEPATOLOGY
(2021)
Article
Endocrinology & Metabolism
LingHong Huang, ZhengRong Jiang, JingXiong Zhou, YuPing Chen, HuiBin Huang
Summary: This study investigated the effect of inactivated SARS-CoV-2 vaccines on thyroid function and thyrotropin receptor antibody (TRAB) levels. The results showed that TRAB levels decreased less after vaccination and exhibited an upward trend, which may be related to humoral immunity induced by the vaccine.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Immunology
Athanasios G. Tzioufas, Athanasios-Dimitrios Bakasis, Andreas Goules, Kleopatra Bitzogli, Ilir I. Cinoku, Loukas G. Chatzis, Ourania D. Argyropoulou, Aliki Venetsanopoulou, Maria Mavrommati, Ioanna E. Stergiou, Vasilis Pezoulas, Paraskevi V. Voulgari, Chaido Katsimpari, Spyridon Katechis, Souzana Gazi, Gkikas Katsifis, Charalampos Sfontouris, Athanasios Georgountzos, Stamatis-Nick Liossis, Charalampos Papagoras, Dimitrios Fotiadis, Fotini N. Skopouli, Panayiotis G. Vlachoyiannopoulos, Haralampos M. Moutsopoulos
Summary: mRNA SARS-CoV-2 vaccines are effective and safe in SAARD patients, with extended treatment modifications leading to better antibody responses. Treatment with MMF, RTX, and MTX may compromise vaccine-induced antibody responses.
JOURNAL OF AUTOIMMUNITY
(2021)
Review
Immunology
Jeffrey Cohen, Peter D. Burbelo
Summary: The likelihood and duration of reinfection with SARS-CoV-2 remain uncertain, as current knowledge on this topic is limited. Studies on other respiratory viruses suggest that serum antibodies typically persist for only a few months to a few years, making reinfections common. These findings have implications for vaccine development and the need for continued protective measures.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Immunology
Susanna Esposito, Caterina Caminiti, Rosanna Giordano, Alberto Argentiero, Greta Ramundo, Nicola Principi
Summary: Inflammatory bowel diseases are chronic immune-related conditions that may occur in genetically susceptible individuals. Patients with IBD are not significantly more susceptible to SARS-CoV-2 infection, and if infected, most cases do not require modification of existing therapy. Corticosteroids should be reduced or suspended to avoid severe forms. Further studies are needed to understand the impact of SARS-CoV-2 variants on IBD and the immune response to infection and vaccination.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Endocrinology & Metabolism
Abubakr Mohamed, Ploutarchos Tzoulis, Andrea Lora Kossler, Chrysoula Dosiou
Summary: This study describes two cases of thyroid eye disease (TED) activation following mRNA SARS-CoV-2 vaccination and reviews additional cases reported in the literature. The results show that new-onset TED or deterioration of previously stable TED can occur after SARS-CoV-2 vaccination, with most cases occurring in patients with underlying autoimmune thyroid disease.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Philippe Caron
Summary: Since the emergence of the Covid-19 pandemic, various types of vaccines have been developed and a global vaccination campaign has been underway. There has been an increasing number of SARS-CoV-2 vaccine-induced thyroid diseases, with subacute thyroiditis and Graves' disease being the most common. This study discusses the underlying mechanisms of vaccine-induced thyroid diseases and highlights the importance of clinicians being aware of and monitoring for thyroid-related symptoms in patients following SARS-CoV-2 vaccination.
Article
Immunology
Yuling Han, Jiaxin Yang, Danshuang He, Yang Feng, Xiaoman Liu, Yu Min, Shenghao Fan, Guobing Yin, Daixing Hu
Summary: This study assessed the safety and immunogenicity of SARS-CoV-2 vaccines in patients with thyroid cancer. The results showed that SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. However, the duration of immune response is shorter in these patients compared to healthy adults. Therefore, a booster vaccination may be recommended earlier for thyroid cancer patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Multidisciplinary
Moustafa T. Mabrouk, Wei-Chiao Huang, Luis Martinez-Sobrido, Jonathan F. Lovell
Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to millions of deaths globally and emphasized the importance of vaccines. Advanced technologies have enabled rapid development and deployment of COVID-19 vaccines, although access is limited in many developing countries. Different vaccine platforms and nanomaterials have been used to develop COVID-19 vaccines. Continued development of vaccine technologies is crucial for dealing with the ongoing and future pandemics.
ADVANCED MATERIALS
(2022)
